Home / Compare / Share of global biopharmaceutical pipeline vs Alzheimer's disease drug trial starts in China Share of global biopharmaceutical pipeline vs Alzheimer's disease drug trial starts in China In 2025, share of global biopharmaceutical pipeline in China was 30%; alzheimer's disease drug trial starts was 16.
Change the pair
Compare different indicators The series
Over time China, annual figures, spaced by time
. Different units, drawn on separate scales
.
Read the values, not the heights.
Share of global biopharmaceutical pipeline
Unit: % · 2 observations
Line chart Share of global biopharmaceutical pipeline Share of global biopharmaceutical pipeline. 2 observations from 2015 to 2025, ranging from 2% to 30%. Latest value 30% (2025).
%
0
10
20
30
2015
2017
2019
2021
2023
2025
2%
30%
Share of global biopharmaceutical pipeline Share of global biopharmaceutical pipeline. 2 observations from 2015 to 2025, ranging from 2% to 30%. Latest value 30% (2025).
%
0
10
20
30
2015
2017
2019
2021
2023
2025
2%
30%
Share of global biopharmaceutical pipeline Share of global biopharmaceutical pipeline. 2 observations from 2015 to 2025, ranging from 2% to 30%. Latest value 30% (2025).
%
0
10
20
30
2015
2017
2019
2021
2023
2025
2%
30%
View the underlying data Alzheimer's disease drug trial starts
Unit: count · 6 observations
Line chart Alzheimer's disease drug trial starts Alzheimer's disease drug trial starts. 6 observations from 2020 to 2025, ranging from 5 to 16. Latest value 16 (2025).
0
5
10
15
20
2015
2017
2019
2021
2023
2025
6
16
Alzheimer's disease drug trial starts Alzheimer's disease drug trial starts. 6 observations from 2020 to 2025, ranging from 5 to 16. Latest value 16 (2025).
0
5
10
15
20
2015
2017
2019
2021
2023
2025
6
16
Alzheimer's disease drug trial starts Alzheimer's disease drug trial starts. 6 observations from 2020 to 2025, ranging from 5 to 16. Latest value 16 (2025).
0
5
10
15
20
2015
2017
2019
2021
2023
2025
6
16
View the underlying data Shared periods
Side by side Only one period is published for both
series in China as annual figures on the same
basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from Proportion of global biopharmaceutical research and development pipeline assets originating from a specific country or region.
2 observations charted in China
· source organisations: State Council
Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in China
· source organisations: ClinicalTrials.gov
Data published under CC BY 4.0 .
Series A as JSON · Series B as JSON